Alec Aeby

Alec Aeby


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GRGillian I Rice
Gillian I Rice
JBJacquelyn Bond
Jacquelyn Bond
AAAruna Asipu
Aruna Asipu
RBRebecca L Brunette
Rebecca L Brunette
IMIain Manfield
Iain Manfield
YCYanick J Crow
Yanick J Crow

16 January 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YCYanick J. Crow
Yanick J. Crow
DCDiana S. Chase
Diana S. Chase
JSJohanna Lowenstein Schmidt
Johanna Lowenstein Schmidt
MSMarcin Szynkiewicz
Marcin Szynkiewicz
GFGabriella M.A. Forte
Gabriella M.A. Forte
GRGillian I. Rice
Gillian I. Rice

1 December 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
GRGillian I Rice
Gillian I Rice
GFGabriella M A Forte
Gabriella M A Forte
MSMarcin Szynkiewicz
Marcin Szynkiewicz
DCDiana S Chase
Diana S Chase
AAAlec Aeby
Alec Aeby
YCYanick J Crow
Yanick J Crow

1 October 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GRGillian Rice
Gillian Rice
TPTeresa Patrick
Teresa Patrick
RPRekha Parmar
Rekha Parmar
CTClaire F. Taylor
Claire F. Taylor
AAAlec Aeby
Alec Aeby
YCYanick J. Crow
Yanick J. Crow

29 April 2010 in Brain
Verified
Journal Article
Open access
PDF file
MWMichèl Willemsen
Michèl Willemsen
MVMarcel M. Verbeek
Marcel M. Verbeek
EKErik-Jan Kamsteeg
Erik-Jan Kamsteeg
JAJohanneke F. de Rijk-Van Andel
Johanneke F. de Rijk-Van Andel
AAAlec Aeby
Alec Aeby
RWRon A. Wevers
Ron A. Wevers
Tyrosine hydroxylase deficiency is an autosomal recessive disorder resulting from cerebral catecholamine deficiency. Tyrosine hydroxylase deficiency has been reported in fewer than 40 patients worldwide. To recapitulate all available evidence on clinical phenotypes and rational diagnostic and therapeutic approaches for this devastating, but treatable, neurometabolic disorder, we studied 36 patients with tyrosine hydroxylase deficiency and reviewed the literature. Based on the presenting neurological features, tyrosine hydroxylase deficiency can be divided in two phenotypes: an infantile onset, progressive, hypokinetic-rigid syndrome with dystonia (type A), and a complex encephalopathy with neonatal onset (type B). Decreased cerebrospinal fluid concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol, with normal 5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the biochemical hallmark of tyrosine hydroxylase deficiency. The homovanillic acid concentrations and homovanillic acid/5-hydroxyindoleacetic acid ratio in cerebrospinal fluid correlate with the severity of the phenotype. Tyrosine hydroxylase deficiency is almost exclusively caused by missense mutations in the TH gene and its promoter region, suggesting that mutations with more deleterious effects on the protein are incompatible with life. Genotype–phenotype correlations do not exist for the common c.698G>A and c.707T>C mutations. Carriership of at least one promotor mutation, however, apparently predicts type A tyrosine hydroxylase deficiency. Most patients with tyrosine hydroxylase deficiency can be successfully treated with l-dopa.

1 August 2022 in Radiology
Verified
Journal Article
Closed access
OFOdile Feys
Odile Feys
PCPierre Corvilain
Pierre Corvilain
AAAlec Aeby
Alec Aeby
CSClaudine Sculier
Claudine Sculier
NHNiall Holmes
Niall Holmes
XTXavier De Tiège
Xavier De Tiège
On-scalp optically pumped magnetometer-based magnetoencephalography provided a higher amplitude and signal-to-noise ratio than cryogenic magnetoencephalography, with similar localization value, for... Background Magnetoencephalography (MEG) is an established method used to detect and localize focal interictal epileptiform discharges (IEDs). Current MEG systems house hundreds of cryogenic sensors...